Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 02:44PM ET
0.3681
Dollar change
-0.0119
Percentage change
-3.13
%
Index- P/E- EPS (ttm)-0.44 Insider Own- Shs Outstand23.63M Perf Week-44.11%
Market Cap8.70M Forward P/E- EPS next Y- Insider Trans- Shs Float23.62M Perf Month62.88%
Income-10.40M PEG- EPS next Q- Inst Own1.57% Short Float0.20% Perf Quarter-6.81%
Sales0.00M P/S- EPS this Y91.72% Inst Trans21.85% Short Ratio0.00 Perf Half Y5.17%
Book/sh0.14 P/B2.70 EPS next Y- ROA-58.59% Short Interest0.05M Perf Year-57.20%
Cash/sh0.10 P/C3.58 EPS next 5Y- ROE-181.74% 52W Range0.19 - 1.58 Perf YTD-16.25%
Dividend Est.- P/FCF- EPS past 5Y4.22% ROI-289.47% 52W High-76.70% Beta2.16
Dividend TTM- Quick Ratio0.71 Sales past 5Y-25.00% Gross Margin- 52W Low97.27% ATR (14)0.15
Dividend Ex-Date- Current Ratio0.71 EPS Y/Y TTM64.58% Oper. Margin0.00% RSI (14)47.38 Volatility24.91% 35.06%
Employees- Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q61.57% Payout- Rel Volume0.19 Prev Close0.38
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume12.79M Price0.37
SMA20-14.83% SMA5011.11% SMA200-7.89% Trades Volume1,936,920 Change-3.13%
Date Action Analyst Rating Change Price Target Change
Oct-14-21Initiated Maxim Group Buy $18
Jan-05-21Initiated H.C. Wainwright Buy $17
Jul-12-24 11:24AM
10:08AM
07:41AM
Jul-11-24 01:26PM
01:01PM
12:51PM Loading…
12:51PM
12:31PM
07:29AM
06:32AM
Jul-10-24 12:42PM
12:08PM
11:57AM
07:30AM
Jun-27-24 08:15AM
May-23-24 02:41PM
07:39AM Loading…
May-21-24 07:39AM
May-02-24 04:22AM
May-01-24 08:45AM
Mar-24-24 07:55AM
Mar-21-24 08:52AM
Mar-13-24 08:00AM
Feb-21-24 07:30AM
Jan-18-24 07:30AM
Dec-05-23 06:02PM
Dec-01-23 08:00AM
Nov-29-23 07:01AM
Nov-21-23 07:30AM
Nov-20-23 04:30PM
Nov-15-23 08:30AM
Nov-10-23 07:01AM
07:01AM Loading…
Nov-01-23 07:01AM
Oct-23-23 07:01AM
Oct-11-23 07:01AM
Oct-05-23 07:01AM
Sep-29-23 07:01AM
Jul-06-23 07:00AM
Jun-08-23 07:00AM
May-25-23 07:01AM
Apr-14-23 07:01AM
Apr-04-23 07:00AM
Jan-25-23 03:03PM
Jan-18-23 11:50AM
Jan-16-23 07:01AM
Dec-19-22 09:00PM
Dec-15-22 07:01AM
Dec-12-22 07:01AM
Dec-01-22 07:01AM
Nov-28-22 04:50PM
Nov-09-22 07:00AM
Nov-02-22 07:10AM
Oct-27-22 10:48AM
07:00AM
Oct-06-22 08:00AM
Sep-26-22 09:55AM
Sep-09-22 08:00AM
Sep-08-22 06:00PM
Sep-07-22 10:35AM
Aug-11-22 09:55AM
Aug-05-22 10:00AM
08:40AM
Aug-01-22 07:00AM
Jul-17-22 06:28PM
Jul-12-22 08:15AM
Jul-06-22 07:00AM
Jun-17-22 08:00AM
Jun-13-22 07:00AM
Jun-08-22 08:49PM
Jun-07-22 07:00AM
Jun-03-22 07:00AM
May-31-22 07:00AM
May-26-22 07:50AM
May-23-22 08:30AM
May-17-22 08:00AM
May-16-22 09:12PM
Apr-29-22 11:00AM
Apr-08-22 08:30AM
08:00AM
Mar-30-22 07:35AM
Mar-28-22 05:46AM
Mar-21-22 08:00AM
Feb-28-22 08:00AM
Feb-07-22 02:25PM
08:00AM
Jan-25-22 08:00AM
Jan-07-22 08:00AM
Dec-24-21 02:33PM
Dec-13-21 11:00AM
Dec-04-21 08:00AM
Nov-29-21 08:00AM
Nov-28-21 09:47PM
Nov-15-21 11:00AM
Nov-11-21 08:00AM
Nov-04-21 08:00AM
Nov-03-21 08:38PM
Oct-14-21 11:15AM
Oct-13-21 05:42PM
Oct-06-21 10:00AM
Sep-10-21 12:30PM
Sep-07-21 06:36PM
Aug-02-21 05:31PM
Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.